Tweet
Hello everyone, has anyone tried to modify the amount of tranposome during tagmantation using Nextera? We have already modified the protocol with good results concerning tagmentation time, but we are now considering of decreasing TD and I am worried if this would work....Does anyone know if the Rd1 and Rd2 seq primers are in the TD tube or in the TDE tube (which we do not plan to decrease)?
-
-
I do not know what your aim is to modify the Illumina protocol. TD is 2x tagmentation buffer and if you are planning to modify its amount you will need to proportionally modify your reaction volume. TDE tube contains transposon complex which inserts 19 bp transposase recognition sequences appended with 14-15 nt overhangs to DNA in tagmentation reaction that are used during PCR to add sequencing and flow cell binding motives and index sequences. R1 and R2 sequencing primers come with sequencing kit (MiSeq) or as separate kit which are added to SBS reagents in HiSeq systems. -
I am sorry I meant decreasing TDE!!!!!!!!!!!!!!!!Comment
-
Decreasing TDE without any other modification will results in larger fragments. If you reduce TDE only , then you will not have enough buffer to use it in other reactions. So, if you are aiming for larger fragments it would make more sense to reduce reaction volume (TD, TDE and input DNA) and keep the input DNA amount the same.Comment
-
yes I am aiming for larger fragments! thanks for the info!Comment
-
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
Comment